Display options
Cite
Karer M, Haider T, Kussmann M, et al. Treatment of legionellosis including a single intravenous dose of 1.5 g azithromycin: 18-year experience at a tertiary care hospital. Int J Antimicrob Agents. 2021;59(1):106481doi: 10.1016/j.ijantimicag.2021.106481.
Karer, M., Haider, T., Kussmann, M., Obermüller, M., Tiehen, C., Burgmann, H., Lagler, H., & Traby, L. (2022). Treatment of legionellosis including a single intravenous dose of 1.5 g azithromycin: 18-year experience at a tertiary care hospital. International journal of antimicrobial agents, 59(1), 106481. https://doi.org/10.1016/j.ijantimicag.2021.106481
Karer, Matthias, et al. "Treatment of legionellosis including a single intravenous dose of 1.5 g azithromycin: 18-year experience at a tertiary care hospital." International journal of antimicrobial agents vol. 59,1 (2022): 106481. doi: https://doi.org/10.1016/j.ijantimicag.2021.106481
Karer M, Haider T, Kussmann M, Obermüller M, Tiehen C, Burgmann H, Lagler H, Traby L. Treatment of legionellosis including a single intravenous dose of 1.5 g azithromycin: 18-year experience at a tertiary care hospital. Int J Antimicrob Agents. 2022 Jan;59(1):106481. doi: 10.1016/j.ijantimicag.2021.106481. Epub 2021 Nov 18. PMID: 34801678.
Copy Download .nbib Format: NLM
Share it on

Int J Antimicrob Agents. 2022 Jan;59(1):106481. doi: 10.1016/j.ijantimicag.2021.106481. Epub 2021 Nov 18.

Treatment of legionellosis including a single intravenous dose of 1.5 g azithromycin: 18-year experience at a tertiary care hospital.

International journal of antimicrobial agents

Matthias Karer, Teresa Haider, Manuel Kussmann, Markus Obermüller, Claas Tiehen, Heinz Burgmann, Heimo Lagler, Ludwig Traby

Affiliations

  1. Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria; Department of Clinical Pharmacology, Medical University Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
  2. Department of Neurophysiology, Center for Brain Research, Medical University Vienna, Spitalgasse 4, 1090 Vienna, Austria.
  3. Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
  4. Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria. Electronic address: [email protected].

PMID: 34801678 DOI: 10.1016/j.ijantimicag.2021.106481

Abstract

OBJECTIVES: Due to recent safety concerns regarding fluoroquinolones and the potential medical and economic benefits, we investigated the efficacy of a single intravenous dose of 1.5 g azithromycin for the treatment of pulmonary legionellosis.

METHODS: Using a nationwide legionellosis registry for pre-selection, 74 patients admitted from 2000-2018 to a tertiary care hospital owing to pneumonia caused by Legionella pneumophila were retrospectively included in this study.

RESULTS: Conventional treatment regimens consisting of fluoroquinolones (n = 20), macrolides (n = 30) or combinations of both (n = 24) and a single intravenous dose of azithromycin (n = 12) have been demonstrated to be equally effective. Single-dose azithromycin treatment was well tolerated and resulted in a shorter hospital stay (P = 0.0464) and shorter antibiotic treatment duration (P = 0.0004) allowing earlier discharge.

CONCLUSION: A single intravenous dose of azithromycin might be a valuable treatment alternative for patients with legionellosis.

Copyright © 2021 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.

Keywords: Antimicrobial therapy; Azithromycin; Fluoroquinolones; Legionella pneumophila; Legionnaires’ disease; Pneumonia

Publication Types